Literature DB >> 30991021

Oncogenic KRAS Drives Immune Suppression in Colorectal Cancer.

Kay Hänggi1, Brian Ruffell2.   

Abstract

In this issue of Cancer Cell, Liao et al. demonstrate that oncogenic KRAS drives an immune suppressive program in colorectal cancer by repressing IRF2 expression, which leads to downregulation of interferon responsive genes, enhanced expression of CXCL3 and recruitment of suppressive myeloid cells, and subsequent resistance to immune checkpoint blockade.
Copyright © 2019 Elsevier Inc. All rights reserved.

Entities:  

Year:  2019        PMID： 30991021     DOI： 10.1016/j.ccell.2019.03.008

Source DB:  PubMed          Journal:  Cancer Cell        ISSN： 1535-6108            Impact factor:   31.743


  8 in total

1.  Resistance to Immunotherapy: Mechanisms and Means for Overcoming.

Authors:  Mohamad A Salkeni; John Y Shin; James L Gulley
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

Review 2.  Tumor Genotype Is Shaping Immunophenotype and Responses to Immune Checkpoint Inhibitors in Solid Tumors.

Authors:  Kathrina L Marcelo-Lewis; Shhyam Moorthy; Ecaterina Ileana-Dumbrava
Journal:  J Immunother Precis Oncol       Date:  2020-08-05

3.  KRAS Promoter Methylation Status and miR-18a-3p and miR-143 Expression in Patients With Wild-type KRAS Gene in Colorectal Cancer.

Authors:  Jehison Alirio Herrera-Pulido; Orlando Ricaurte Guerrero; Jinneth Acosta Forero; Pablo Moreno-Acosta; Alfredo Romero-Rojas; Carolina Sanabria; Gustavo Hernández; Martha Lucía Serrano
Journal:  Cancer Diagn Progn       Date:  2022-09-03

4.  KRAS signaling enriched triple negative breast cancer is associated with favorable tumor immune microenvironment and better survival.

Authors:  Yoshihisa Tokumaru; Masanori Oshi; Eriko Katsuta; Li Yan; Vikas Satyananda; Nobuhisa Matsuhashi; Manabu Futamura; Yukihiro Akao; Kazuhiro Yoshida; Kazuaki Takabe
Journal:  Am J Cancer Res       Date:  2020-03-01       Impact factor: 6.166

5.  Prediction and identification of immune genes related to the prognosis of patients with colon adenocarcinoma and its mechanisms.

Authors:  Sihan Chen; G D Cao; Wu Wei; Lu Yida; He Xiaobo; Yang Lei; Chen Ke; Bo Chen; Mao Ming Xiong
Journal:  World J Surg Oncol       Date:  2020-06-29       Impact factor: 2.754

Review 6.  Inflammatory signaling in genomically instable cancers.

Authors:  Francien Talens; Marcel A T M Van Vugt
Journal:  Cell Cycle       Date:  2019-07-10       Impact factor: 4.534

7.  Immuno-genomic classification of colorectal cancer organoids reveals cancer cells with intrinsic immunogenic properties associated with patient survival.

Authors:  Eun Jeong Cho; Minsuh Kim; Daum Jo; Jihye Kim; Ji-Hye Oh; Hee Chul Chung; Sun-Hye Lee; Deokhoon Kim; Sung-Min Chun; Jihun Kim; Hyeonjin Lee; Tae Won Kim; Chang Sik Yu; Chang Ohk Sung; Se Jin Jang
Journal:  J Exp Clin Cancer Res       Date:  2021-07-13

Review 8.  Signaling pathways in intestinal homeostasis and colorectal cancer: KRAS at centre stage.

Authors:  Camille Ternet; Christina Kiel
Journal:  Cell Commun Signal       Date:  2021-03-10       Impact factor: 5.712
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.